Search

Your search keyword '"Foglietta, Myriam"' showing total 172 results

Search Constraints

Start Over You searched for: Author "Foglietta, Myriam" Remove constraint Author: "Foglietta, Myriam"
172 results on '"Foglietta, Myriam"'

Search Results

1. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

2. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

3. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

4. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

5. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia:A study by ERIC, the European research initiative on CLL

6. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

7. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

8. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

9. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

10. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells

11. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

12. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL

14. Worldwide Examination of Patients with CLL Hospitalized for COVID-19

16. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

17. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report

18. COVID-19 severity and mortality in patients with CLL:an update of the international ERIC and Campus CLL study

19. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

21. Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases

22. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia:a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

28. ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and Vγ9Vδ2 T-Cell Activation By Dendritic Cells

30. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia

31. The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection

38. Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL)

40. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells

41. Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma

46. The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells

48. Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)

49. The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)

50. PD-1+ T Cell Subsets in Follicular Lymphoma Tumor Microenvironment and Their Implications for Prognosis and Therapy

Catalog

Books, media, physical & digital resources